BA 015 gene therapy

Drug Profile

BA 015 gene therapy

Alternative Names: AMEP; BA-015 AMEP peptide; p-AMEP; Plasmid AMEP; Synfoldin

Latest Information Update: 09 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioAlliance Pharma
  • Developer BioAlliance Pharma; Onxeo SA
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action ADAM protein inhibitors; Angiogenesis inhibitors; Gene transference; Integrin alpha 5 beta 1 inhibitors; Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma; Solid tumours

Most Recent Events

  • 09 Dec 2014 Discontinued - Phase-I/II for Malignant melanoma in France (IM)
  • 09 Dec 2014 Discontinued - Phase-I/II for Malignant melanoma in Slovenia (IM)
  • 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top